No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 PandemicArticle Published on 2020-11-132023-07-12 Journal: The Journal of Infectious Diseases [Category] SARS, [키워드] COVID-19 Intravenous immunoglobulin Neutralizing antibodies plasma Primary Immunodeficiency SARS coronavirus 2 antibody titer SARS-CoV-2 [DOI] 10.1093/infdis/jiaa593 PMC 바로가기
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease SeverityArticle Published on 2020-11-122022-10-04 Journal: Cell [Category] Fulltext, SARS, 유전자 메커니즘, [키워드] acute COVID-19 adaptive Adaptive immune response Adaptive immunity aging antibody Antibody Response Arm Biomarker CD4 CD8 connection convalescent coronavirus COVID-19 COVID-19 disease severity CXCL10 disease disease severity Epitopes highlighting identify immune response Immunity individual IP-10 knowledge limit Limited Multiple Neutralizing antibodies Neutralizing antibody response outcomes Protective protective immunity response responses risk factor SARS-CoV-2 scarcity severe COVID-19 spike subjects T cells [DOI] 10.1016/j.cell.2020.09.038 PMC 바로가기 [Article Type] Article
Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to 6 months post disease onset질병 발병 후 최대 6개월까지 COVID-19 환자 및 건강한 지원자에서 항-SARS-CoV-2 항체의 혈청유병률Clinical Trial Published on 2020-11-102022-08-13 Journal: European Journal of Immunology [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] age Anti‐SARS‐CoV‐2 antibody response Anti‐SARS‐CoV‐2 antibody responses anti‐SARS‐CoV‐2 IgG antibody antibody antibody production Antibody Response Antibody titer Asymptomatic circulating classic Clinical signs COVID‐19 COVID‐19 patient COVID‐19 described detect detectable disease onset Fever healthcare Healthcare workers healthy volunteer highlight hospital human pathogen humoral immune response IgA antibodies IgA antibody IgG IgG antibodies IgM immune response immunological information initial longitudinal analysis men Mild MONITOR neutralising antibody neutralization activity Neutralizing antibodies Patient peaking proportion protective immunity Protein provide quantified rapid increase RBD receptor‐binding domain recognizing reduce remained robust SARS‐CoV‐2 SARS‐CoV‐2 screened Seroprevalence setup Severity of disease Spread subject subjects Symptoms tested the Spike titre titres university virus volunteers were infected [DOI] 10.1002/eji.202048970 PMC 바로가기 [Article Type] Clinical Trial
SARS-CoV-2 and interferon blockadeReview Published on 2020-11-092022-10-30 Journal: Molecular Medicine [Category] COVID-19, SARS, [키워드] activate Activation Adaptive immune response block blockade Cytotoxic T cell effective Implications include innate immune system interferon Neutralizing antibodies Pathways reduce SARS-CoV-2 therapeutic viral infection [DOI] 10.1186/s10020-020-00231-w PMC 바로가기 [Article Type] Review
Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overviewReview Published on 2020-11-082023-06-15 Journal: Immunologic research [Category] MERS, SARS, [키워드] epitope glycoprotein humoral immune response monoclonal Neutralizing antibodies phage display polyclonal [DOI] 10.1007/s12026-020-09159-z PMC 바로가기 [Article Type] Review
Convalescent Plasma against COVID-19: A Broad-Spectrum Therapeutic Approach for Emerging Infectious DiseasesReview Published on 2020-11-052022-10-29 Journal: Microorganisms [Category] COVID-19, [키워드] acute respiratory syndrome Algorithm Antiviral Antiviral treatment Blood clinical study convalescent plasma coronavirus coronavirus disease COVID-19 COVID-19 pandemic drug effective Efficacy Emergency use authorization evaluate Evidence FDA feasible food Health authority healthcare implementation Infectious disease lack Neutralizing antibodies Outbreaks pandemic Pandemics pathogen Patient Preliminary data preparedness SARS-CoV-2 Therapeutic approach therapeutic intervention therapy therapy for COVID-19 Vaccine [DOI] 10.3390/microorganisms8111733 PMC 바로가기 [Article Type] Review
Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical EvaluationArticle Published on 2020-11-042022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] ACE2 acute respiratory syndrome added Antigen approaches binding bioreactor Cell cells conformational coronavirus COVID-19 COVID-19 therapeutics COVID-19 vaccine Culture cultures demonstrated downstream efficient Epitopes evaluated exhibited expression functional HEK293SF suspension cells Improvements Infection mechanism media monoclonal antibody motif Neutralizing antibodies Plasmid Production Protein Rapid RBD Research resulting SARS-CoV-2 SARS-CoV-2 Spike Receptor Binding Domain sialic acid spike subunit supernatants Support the RBD protein the Spike Transient transient transfection upstream Vaccine vaccine bioprocess virus [DOI] 10.3390/vaccines8040654 PMC 바로가기 [Article Type] Article
COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune ResponseReview Published on 2020-11-032022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] candidate caused clinical clinical trials Convalescent patients COVID-19 COVID-19 pandemic death determine develop effective Efficacy effort Human immune response impacted implication Infection Neutralizing antibodies Preclinical preclinical studies recovered COVID-19 patient response SARS-CoV-2 T-cell responses Vaccine vaccine candidate Vaccine development vaccine platform vaccine platforms vaccine response [DOI] 10.3390/vaccines8040649 PMC 바로가기 [Article Type] Review
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods경미한 영향을 받은 COVID-19 회복기 환자의 낮은 혈청 중화 항-SARS-CoV-2 S 항체 수준이 두 가지 다른 검출 방법으로 밝혀짐Article Published on 2020-11-022022-09-11 Journal: Cellular and Molecular Immunology [Category] Fulltext, MERS, 진단, 치료기술, 치료제, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 affected age angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 Anti-SARS-CoV-2 S anti-SARS-CoV-2 S1 IgG antibodies antibody binding biosafety Cell clinical symptom Clinical symptoms convalescent patient Convalescent patients coronavirus coronavirus disease Coronavirus disease 2019 correlated correlated strongly COVID-19 COVID-19 convalescent patient COVID-19 convalescent patients Donor ELISA enzyme faster IgA antibodies Infection interfere less Neutralization assay neutralization test Neutralizing Neutralizing antibodies neutralizing antibody passive antibody therapy Patient patient age plasma Predictive markers Prevalence RBD Receptor-binding domain respiratory S protein S1 IgG SARS-CoV-2 SARS-CoV-2 S SARS-CoV-2 spike sera serum serum antibodies serum antibody severe acute respiratory syndrome Coronavirus severity stomatitis surrogate virus neutralization test sVNT the receptor-binding domain the SARS-CoV-2 vesicular stomatitis vesicular stomatitis virus viral infection virus neutralization test VSV [DOI] 10.1038/s41423-020-00573-9 PMC 바로가기 [Article Type] Article
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric virusesTechnical Advances and Resources Published on 2020-11-022022-10-29 Journal: The Journal of Experimental Medicine [Category] COVID-19, SARS, [키워드] antiviral activity approach chimeric convalescent plasma correlated described disease epidemic of COVID-19 exhibited HIV-1 Human immunodeficiency virus human monoclonal antibodies Human monoclonal antibody Immunity monoclonal antibody neutralization potency Neutralizing activity Neutralizing antibodies plasma pseudotyped reporter robust SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 neutralization SARS-CoV-2 neutralizing antibody SARS-CoV-2–specific antibodies sensitivity stomatitis vaccination vesicular stomatitis virus virus VSV while [DOI] 10.1084/jem.20201181 PMC 바로가기 [Article Type] Technical Advances and Resources